Fatal X-linked ataxia with deafness and loss of vision is a rare inherited disease that affects how cells make purines and pyrimidines—the basic “building blocks” for DNA, RNA, and important energy molecules like ATP and GTP. The problem starts with a change (mutation) in the PRPS1 gene. This gene makes an enzyme called phosphoribosyl-pyrophosphate synthetase 1 (PRS-I). When the enzyme works poorly, nerve and immune cells do not get enough of those building blocks or energy. This leads to weak muscles, delayed milestones, poor balance (ataxia), early hearing loss, vision loss from optic atrophy, frequent infections, and progressive disability. In boys, the illness is usually severe and can be life-limiting; girls may be mildly affected. MedlinePlus+2MedlinePlus+2

Arts syndrome is a rare, inherited condition that mostly affects boys. It causes early balance problems (ataxia), very weak muscles (hypotonia), early and severe hearing loss, and loss of vision from damage to the optic nerve. It often begins in infancy or early childhood and can be life-limiting in males. The root problem is a fault in the PRPS1 gene. That gene makes an enzyme (PRS-I) that creates PRPP, a key “starter molecule” the body needs to build DNA/RNA building blocks (purines and pyrimidines) and energy carriers like ATP and GTP. When PRS-I does not work well, many cells—especially nerves—cannot make enough of these essential molecules, so the brain, ears, eyes, and immune system are hit hard. MedlinePlus+2PMC+2

The PRPS1 gene sits on the X chromosome. Males have one X, so a single harmful change can cause severe disease. Females have two X chromosomes and often have milder or variable features because the healthy copy can partly protect them (depending on X-inactivation). MedlinePlus+1

 Arts syndrome belongs to a continuum of PRPS1-related disorders. When enzyme activity is partly reduced, people may have isolated early deafness (DFN2) or a neuropathy called CMTX5; when the enzyme activity is very low, the severe Arts picture appears with ataxia, optic atrophy, deafness, infections, and early death in males. Nature+1

Other names

• Ataxia, fatal X-linked, with deafness and loss of vision (your term) MedlinePlus

• Ataxia-deafness-optic atrophy, lethal MedlinePlus

• Arts syndrome (preferred medical name) Cell

• Lethal ataxia with deafness and optic atrophy (Orphanet title) Orpha

Types

Doctors do not divide Arts syndrome into formal “subtypes,” but they view it within a PRPS1-related spectrum that runs from mild to severe. Where Arts syndrome sits on this spectrum helps explain differences between patients:

1. Severe PRPS1 deficiency (Arts syndrome): early hypotonia, ataxia, severe to profound hearing loss, optic atrophy, infections, neurodevelopmental delay, and shortened lifespan—mostly in boys. ScienceDirect

2. Intermediate PRPS1 deficiency (CMTX5): X-linked Charcot–Marie–Tooth neuropathy with hearing loss and optic atrophy, often later onset than Arts. Nature

3. Milder PRPS1 deficiency (DFN2): X-linked nonsyndromic sensorineural deafness, usually without the life-threatening features. Nature

4. Female carriers: may show partial features (e.g., mild hearing loss or balance problems) due to X-inactivation patterns. MedlinePlus

Causes

This disease has one primary cause—a harmful change in PRPS1—but many biological consequences and modifiers explain why patients develop ataxia, deafness, and vision loss. The list below spells out those drivers.

1. PRPS1 loss-of-function variants: the root cause; reduce PRS-I enzyme activity. Cell

2. Shortage of PRPP: the key substrate made by PRS-I falls, limiting nucleotide synthesis. MedlinePlus

3. Low purine synthesis: cells cannot make enough ATP/GTP for high-demand tissues like brain and cochlea. MedlinePlus

4. Low pyrimidine synthesis: further starves neurons and glia of building blocks for RNA/DNA. MedlinePlus

5. Energy failure in neurons: ATP shortage impairs axons and synapses, promoting neurodegeneration. ScienceDirect

6. Cochlear hair-cell vulnerability: high-energy sensory cells fail, causing early sensorineural deafness. (Mechanistic inference consistent with PRPS1 deficiency and early deafness.) MedlinePlus

7. Optic nerve susceptibility: retinal ganglion cells/optic nerve degenerate → optic atrophy and vision loss. ScienceDirect

8. Cerebellar circuit dysfunction: contributes to ataxia and poor coordination. ScienceDirect

9. Peripheral neuropathy: some patients show axonal neuropathy that worsens weakness and balance. ScienceDirect

10. Immune cell dysfunction: T-cell abnormalities lead to recurrent infections and clinical decline. ScienceDirect+1

11. Frequent respiratory infections: infections can trigger decompensation and early death. NCBI

12. X-linked inheritance in males: boys have no backup PRPS1 allele, so disease is severe. Genetic Rare Disease Center

13. X-inactivation in females: skewing can unmask symptoms in carriers. MedlinePlus

14. Genotype–phenotype severity: different mutations reduce enzyme activity to different degrees. Nature

15. Developmental window: early brain and ear development are high-demand periods; deficits hit harder. (Inference aligned with early-onset features.) ScienceDirect

16. Poor myelination/axon maintenance: energy shortage hampers long-axon health. (Mechanistic inference within PRPS1 spectrum including CMTX5.) Nature

17. Malnutrition during illness: repeated infections can worsen growth and neurological outcomes. (General clinical effect consistent with GARD’s infection burden.) Genetic Rare Disease Center

18. Limited salvage capacity: insufficient PRPP also weakens the salvage pathway, deepening nucleotide shortage. MedlinePlus

19. De novo PRPS1 variants: occasionally arise without family history, still causing the same biology. Taylor & Francis Online

20. Lack of curative therapy: until disease-modifying treatments are established, natural progression continues. (Context from current literature; case-based metabolic support is investigational.) PMC

Common symptoms and signs

1. Low muscle tone (hypotonia) in infancy makes the baby feel “floppy” and delays sitting or walking. Cell

2. Ataxia—trouble with balance and coordination—appears as unsteady gait and frequent falls. Cell

3. Global developmental delay with slower learning and motor milestones. Cell

4. Sensorineural hearing loss, often severe or profound, starting in early life. Genetic Rare Disease Center

5. Optic atrophy leading to progressive vision loss in childhood or early youth. Cell

6. Weakness and easy fatigue due to low cellular energy. ScienceDirect

7. Peripheral neuropathy (numbness, reduced reflexes) in some patients. Nature

8. Frequent respiratory and other infections, reflecting immune cell dysfunction. NCBI

9. Poor weight gain or failure to thrive during illness clusters. Genetic Rare Disease Center

10. Speech delay and sometimes dysarthria (slurred speech). ScienceDirect

11. Feeding difficulties in infancy due to hypotonia. Cell

12. Behavioral concerns (irritability or lethargy) during infections or fatigue. Genetic Rare Disease Center

13. Visual behaviors such as poor tracking or bumping into objects as vision declines. Cell

14. Gait wide-based posture typical of ataxia. Cell

15. Life-limiting course in many boys if severe and untreated. NCBI

Diagnostic tests

A) Physical examination (bedside)

1. Neurologic exam for hypotonia and reflexes: documents low tone, reduced deep-tendon reflexes, or neuropathic signs. ScienceDirect

2. Cerebellar testing at the bedside: finger-to-nose, heel-to-shin, and tandem gait to confirm ataxia. ScienceDirect

3. Developmental assessment: milestone charting (sitting, walking, speech) to quantify delays. Cell

4. Ophthalmoscopy: direct look at the optic disc to detect pallor typical of optic atrophy. Cell

5. Ear and vestibular check: bedside head-thrust or Romberg to screen vestibular contribution to imbalance. Genetic Rare Disease Center

B) Manual tests (office-based functional checks)

6. Audiology pure-tone testing: measures hearing thresholds across frequencies; typically shows bilateral sensorineural loss. Genetic Rare Disease Center

7. Speech audiometry (word recognition): gauges functional hearing for language. Genetic Rare Disease Center

8. Contrast sensitivity and color vision charts: detect early optic nerve dysfunction beyond visual acuity. Cell

9. Functional gait tests (Timed Up-and-Go): simple quantification of ataxia-related mobility limits. ScienceDirect

10. Manual muscle testing (MRC scale): tracks weakness progression over time. ScienceDirect

C) Laboratory & pathological tests

11. Targeted or panel-based genetic testing of PRPS1: the definitive test; identifies pathogenic variants and enables carrier/prenatal testing. MedlinePlus

12. Enzyme/functional studies (research or specialty): demonstrate reduced PRS-I activity or pathway dysfunction when available. ScienceDirect

13. Immune work-up (lymphocyte subsets, T-cell function): many patients have T-cell abnormalities that raise infection risk. ScienceDirect

14. Metabolic screens (uric acid, purine/pyrimidine intermediates): supportive data within the purine pathway evaluation. MedlinePlus

15. Carrier testing for mothers/female relatives: identifies heterozygous carriers to inform family planning. MedlinePlus

D) Electrodiagnostic tests

16. Auditory brainstem response (ABR): objective measure of sensorineural hearing loss in infants/young children. Genetic Rare Disease Center

17. Electroretinography (ERG) and visual evoked potentials (VEP): quantify retinal/optic pathway dysfunction beyond the eye exam. Cell

18. Nerve conduction studies/electromyography (NCS/EMG): detect peripheral neuropathy sometimes present in PRPS1 disorders. Nature

E) Imaging tests

19. Optical coherence tomography (OCT): shows thinning of the retinal nerve fiber layer typical of optic atrophy. Cell

20. Brain MRI: evaluates cerebellum, brainstem, and optic pathways; rules out other causes of ataxia/vision loss. ScienceDirect

Non-pharmacological treatments (therapies & others)

Core message: Non-drug care does not fix the gene, but greatly improves function, safety, communication, and quality of life, especially when started early.

1. Newborn/early hearing intervention: Fast audiology referral → hearing aids or cochlear implant (CI) candidacy work-up. Early auditory input supports speech and brain development. CI for severe pediatric deafness improves hearing, speech in noise, and life quality; earlier is better. PMC+1

2. Cochlear implantation (where appropriate): In profound loss, CI can provide access to sound when hearing aids fail; evidence from genetic and syndromic deafness shows meaningful gains with proper selection and rehab. PMC+1

3. Low-vision rehabilitation: Magnifiers, contrast enhancement, orientation & mobility training, and school accommodations help children function despite optic atrophy. NCBI

4. Physiotherapy (PT): Balance and core strengthening reduce falls and help gross-motor skills in ataxia. Cell

5. Occupational therapy (OT): Fine-motor training, adaptive utensils, and daily-living strategies increase independence. Cell

6. Speech-language therapy & AAC: Oral-motor, language therapy, and augmentative/alternative communication (signs, picture boards, devices) support communication when hearing/vision are limited. PMC

7. Special education/Individualized learning plan: Early education tailored to hearing/vision impairment and motor challenges optimizes learning. PMC

8. Feeding/Swallow therapy: Safe textures, posture, and pacing reduce aspiration and support growth in hypotonia. Cell

9. Respiratory hygiene: Chest physiotherapy and early treatment of chest infections can prevent complications. Cell

10. Immunization optimization: Staying current with vaccines (including influenza and pneumococcal) reduces infection stress in vulnerable children. (General immune-support principle; T-cell vulnerability reported in Arts.) UQ eSpace

11. Infection prevention routines: Hand hygiene, prompt care of fevers, and early antibiotics when indicated. Cell

12. Assistive listening/learning tech: FM systems, captioning, tactile aids, and classroom acoustics modification. PMC

13. Mobility aids & home safety: Ankle-foot orthoses, walkers, grab bars, and fall-proofing to prevent injuries from ataxia. Cell

14. Nutritional support: High-calorie, protein-adequate diet during illnesses; dietitian input to maintain weight and stamina. Cell

15. Psychological support & family counseling: Coping skills and caregiver support reduce stress and improve adherence. PMC

16. Genetic counseling: Explains inheritance, carrier testing, options for future pregnancies (e.g., prenatal or preimplantation testing). MedlinePlus

17. Vision-hearing combined strategies: Tactile signing, large-print plus amplified sound, and multi-sensory teaching to work around dual sensory loss. PMC

18. School and social inclusion planning: Early placement, disability services, and transport/communication aids. PMC

19. Palliative/complex-care coordination: Symptom relief, goals-of-care talks, and respite services for families facing severe disease. Orpha

20. Clinical trial awareness: Some centers evaluate metabolic supplementation (below) within protocols; families can ask genetics/metabolic teams. Wiley Online Library

---

Drug treatments

Plain warning: There is no approved disease-curing medicine for Arts syndrome yet. The most disease-targeted approach so far is metabolic supplementation aiming to bypass PRPP dependence or bolster nucleotide/energy pools. Evidence remains limited to small studies and case reports, but early results are encouraging.

1. S-adenosyl-L-methionine (SAMe): Oral SAMe provides a purine precursor that does not require PRPP, theoretically helping rescue nucleotide pools; early reports in Arts showed clinical improvement or stabilization. Typical over-the-counter doses vary; use only under specialist guidance in children. Side effects can include GI upset, anxiety, or insomnia. PMC+2ScienceDirect+2

2. Nicotinamide riboside (NR): A precursor of NAD+ that supports cellular energy/redox reactions; case series combining SAMe + NR reported stability or improvement and better T-cell survival in Arts syndrome. Doses were individualized; adverse effects are usually mild (nausea/headache). Wiley Online Library+2PubMed+2

3. Combined SAMe + NR (co-therapy): Reported as biologically synergistic in Arts (nucleotide + NAD pathways). Monitoring by metabolic/genetics teams is essential. Wiley Online Library+1

4. Empiric vitamins (B-complex) as adjuncts: Sometimes used to support general mitochondrial/neurometabolic function; no Arts-specific proof of benefit—use as supportive care only. (General rationale; not disease-modifying.) Nature

5. Infection management antibiotics/antivirals: Early, targeted treatment can prevent decompensation in fragile children; choice depends on culture/guidelines. Cell

6. Immunology-guided care: Selected patients with recurrent infections may benefit from prophylactic antibiotics or immunology input; routine IVIG is not standard in Arts but may be considered case-by-case. UQ eSpace

7. Analgesics/antipyretics (e.g., acetaminophen): Comfort during infections or after procedures; avoids dehydration/worsening weakness. (Supportive.) Cell

8. Antireflux/GI meds (if feeding issues): Reduce aspiration risk and support nutrition. (Supportive.) Cell

9. Antispasticity agents (e.g., baclofen) if tone evolves to mixed patterns; neurology-guided, monitor sedation/weakness. (Symptom-directed.) Cell

10. Antiepileptic drugs (only if seizures occur; not universal in Arts). Choose agents with favorable cognitive/respiratory profiles in children. Cell

11. Melatonin for sleep dysregulation common in neurodevelopmental disorders; improves caregiver resilience. (General pediatric neuro evidence.) Cell

12. Bronchodilators/steroids for reactive airways during infections when clinically indicated. (Supportive.) Cell

13. Nutritional supplements (high-calorie formulas) during illness or growth faltering; medically supervised. Cell

14. Antibiotic prophylaxis around surgeries (e.g., cochlear implant) per ENT protocols. PMC

15. Ophthalmic lubricants/anti-inflammatories for surface comfort; do not reverse optic atrophy. (Supportive vision care.) NCBI

16. Vaccinations (inactivated) as per schedule; medication if needed for fever/comfort. Cell

17. Trial of idebenone or antioxidants (borrowed from other optic neuropathies) is experimental and not proven in Arts—discuss only within specialist care. Nature

18. Appetite stimulants in severe feeding/weight loss situations—short-term, carefully monitored. (Supportive.) Cell

19. Reflux prokinetics if aspiration risk persists after feeding therapy; pediatric GI oversight. (Supportive.) Cell

20. Peri-illness “sick-day” plans (oral rehydration, antipyretics, lower threshold for antibiotics) to blunt metabolic stress. (Supportive.) Cell

---

Dietary molecular supplements

Please use only with specialist supervision in children. Evidence for Arts syndrome is strongest for SAMe and NR; others are adjuncts with theoretical or general neuro-support roles.

1. S-adenosyl-L-methionine (SAMe): See above; purine replenishment bypassing PRPP; early Arts data suggest benefit. PMC

2. Nicotinamide riboside (NR): NAD+ support; combined with SAMe improved clinical stability and T-cell survival in reports. Wiley Online Library+1

3. Uridine (research/adjunct): A pyrimidine nucleoside that can bypass blocks in some pyrimidine defects; not proven in Arts but mechanistically relevant to PRPP-dependent nucleotide balance. Use only in trials/specialist care. chi.gov.sa

4. D-ribose (research/adjunct): A sugar that feeds nucleotide pathways; clinical evidence in PRPS1 deficiency is insufficient—specialist advice only. chi.gov.sa

5. Riboflavin (B2): General mitochondrial cofactor; supportive only. Nature

6. Thiamine (B1): Energy metabolism cofactor; supportive only. Nature

7. Coenzyme Q10: Antioxidant for mitochondrial function; no Arts-specific proof. Nature

8. L-carnitine: Fatty-acid transport; sometimes used in neurometabolic clinics; evidence in Arts lacking. Nature

9. Folate/B12: Methylation and nucleotide synthesis support; correct deficiencies if present. Nature

10. Omega-3 fatty acids: General neurodevelopment support; adjunct only. Nature

---

Immune-booster / regenerative / stem-cell drugs

Straight talk: There are no approved regenerative or stem-cell drugs for Arts syndrome. The items below explain current investigational or supportive directions so families know what to ask about—and what not to expect yet.

1. SAMe (disease-targeted metabolic support): Early clinical benefits reported; not curative. PMC

2. Nicotinamide riboside (supports immune cell survival/energy): Improved T-cell survival with SAMe co-therapy in Arts. UQ eSpace

3. Gene therapy (conceptual, not available): In theory, replacing or correcting PRPS1 could restore PRS-I; no clinical trials reported yet. (Conceptual future direction from PRPS1 biology literature.) Nature

4. Hematopoietic stem-cell transplant (HSCT): Not indicated for Arts; no evidence that HSCT corrects PRPS1 deficiency in target tissues (CNS/inner ear/optic nerve). Families should avoid this outside a trial. (Rationale from disease mechanism/distribution.) Nature

5. mTOR/antioxidant pathways (experimental): General neuroprotection ideas—not tested in Arts; discuss only within research protocols. Nature

6. Immunology-guided biologics: Not standard for Arts; may be used for specific, proven immune defects on a case basis—not to treat the genetic enzyme defect. UQ eSpace

---

Surgeries

1. Cochlear implant (CI): For profound bilateral sensorineural hearing loss when hearing aids do not help. Restores access to sound, improves speech perception and life quality with early implantation and therapy. PMC

2. Gastrostomy tube (G-tube): If severe feeding/aspiration/failure to thrive persists, a G-tube supports safe nutrition and medications. Cell

3. Orthopedic procedures (select children): For contractures or deformities from long-standing hypotonia/neuropathy to improve comfort and care. Cell

4. Strabismus surgery (if significant misalignment): Aligns eyes to improve comfort/appearance and ease low-vision strategies (does not fix optic atrophy). NCBI

5. Airway surgery (rare; for obstructive problems): If aspiration or structural issues cause recurrent pneumonias, ENT may intervene. Cell

---

Preventions

You cannot prevent the genetic change, but you can reduce complications and plan future pregnancies.

1. Newborn hearing screen → rapid referral to audiology/ENT. PMC

2. Early vision and neurology evaluation to start rehab promptly. NCBI

3. Vaccinations (on time). Cell

4. Hand hygiene and quick care for fevers to limit infection stress. Cell

5. Nutrition plans during illness (“sick-day” hydration/calories). Cell

6. Home safety and mobility aids to prevent falls. Cell

7. Genetic counseling for carrier testing and reproductive options. MedlinePlus

8. School supports (IEP, assistive tech) to prevent learning gaps. PMC

9. Coordinated care team (metabolic/genetics, ENT, ophthalmology, PT/OT/SLP). Cell

10. Discuss SAMe/NR with specialists if Arts is confirmed (benefits are suggestive, not proven). Wiley Online Library

---

When to see doctors (red flags)

• Any infant with floppy tone, poor feeding, or delayed milestones, especially with hearing loss → urgent pediatric/neurology/audiology referral. Cell

• Vision concerns (poor tracking, nystagmus, or apparent vision loss) → ophthalmology promptly. NCBI

• Recurrent or severe infections, dehydration, or breathing problems → immediate care; ask about immune evaluation. UQ eSpace

• Confirmed PRPS1 variant → genetics/metabolic clinic to discuss supportive care and SAMe/NR options. Wiley Online Library

---

What to eat and what to avoid

There is no special “Arts diet.” The goal is steady energy, growth, and resilience during illness.

1. Do eat: Balanced meals with adequate protein to support growth and repair. Cell

2. Do eat: Frequent, smaller feeds during illness to maintain calories. Cell

3. Do drink: Enough fluids; use oral rehydration early during fevers. Cell

4. Do include: Iron, B-vitamins, and healthy fats through regular foods; correct any proven deficiencies. Nature

5. Consider (specialist-supervised): SAMe and NR as discussed; avoid self-starting in children. Wiley Online Library

6. Avoid: Crash diets, fasting, or long gaps between feeds (low reserve). Cell

7. Avoid: Unproven online “cures,” large supplement stacks without medical oversight. Nature

8. Avoid: Alcohol/energy drinks in older teens (dehydration, sleep disruption). Cell

9. Be careful with: Herbal products that interact with medicines or appetite. Ask your doctor first. Cell

10. If swallowing is unsafe: Use thickened liquids/texture modifications per therapist to prevent aspiration. Cell

---

FAQs

1) Is Arts syndrome the same as “fatal X-linked ataxia with deafness and vision loss”?
Yes—this older descriptive name refers to Arts syndrome, the severe end of PRPS1 deficiency. Orpha

2) What exactly is broken in the body?
A gene called PRPS1. It makes an enzyme that helps the body build nucleotides and energy molecules. Without enough enzyme activity, high-energy tissues (brain, ear, eye, immune system) struggle. MedlinePlus

3) Why are boys usually worse?
Because PRPS1 is on the X chromosome, and boys have only one X. Girls may be carriers or mildly affected. MedlinePlus

4) How is it diagnosed?
By genetic testing of the PRPS1 gene; other tests document hearing, vision, and nerve involvement. Cell

5) Can hearing aids help?
Mild loss may benefit from hearing aids, but many children have profound loss and need cochlear implants plus therapy. PMC

6) Will a cochlear implant restore normal hearing?
It does not make hearing “normal,” but it opens access to sound. Early implantation plus therapy improves speech and quality of life. PMC

7) Can vision be restored?
Optic atrophy is not reversible. Low-vision rehab and educational supports make a big difference. NCBI

8) Are there medicines that treat the root problem?
Emerging: SAMe and nicotinamide riboside have shown stability or improvement in small Arts reports. They are not a cure. Wiley Online Library

9) Should we try many supplements?
Please don’t self-start. Outside SAMe/NR with specialist oversight, evidence is weak. Focus on early rehab, nutrition, infection prevention, and school supports. Wiley Online Library

10) Is gene therapy available?
Not yet. It is a theoretical future option for PRPS1, but no human trials are available. Nature

11) What is the life expectancy?
Historically, severe Arts in boys was life-limiting. With early hearing/vision support, infection control, nutrition, and attentive care, outcomes can improve, but exact modern data are limited. Orpha

12) Can girls be affected?
Yes, but usually milder because of the second X chromosome; some girls have significant symptoms. MedlinePlus

13) We have a PRPS1 variant—what next?
Meet genetics/metabolic specialists; discuss SAMe/NR and comprehensive rehab; set up hearing/vision services quickly. Wiley Online Library

14) Is Arts syndrome related to CMT or isolated deafness?
Yes, all three (Arts, CMTX5, DFN2) sit on a PRPS1 spectrum linked to how much enzyme function remains. Nature

15) Where can I read more?
Good medical summaries: GeneReviews/NCBI Bookshelf (PRPS1 disorders), MedlinePlus Genetics, and recent case series on SAMe/NR therapy. NCBI+2MedlinePlus+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 24, 2025.